Acquired Company
Ginkgo Bioworks completed its acquisition of Zymergen on 10/19/2022 via an all-stock transaction in which Zymergen stockholders received 0.9179 shares of Ginkgo Class A common stock for each Zymergen share.
Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$2.43
Open
$2.43
Volume
85
Day Range
$2.43 - $2.43
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Farabursen (RGLS8429) Details Autosomal Dominant Polycystic Kidney Disease, Kidney disease | Phase 1b Update |